Literature DB >> 16050674

Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides.

Weiming Luo1, Qian-Sheng Yu, Harold W Holloway, Damon Parrish, Nigel H Greig, Arnold Brossi.   

Abstract

5-Hydroxy-3-methyl-3H-benzofuran-2-one, 5, easily obtained from pyruvic acid and 1,4-cyclohexanedione, was used as a starting material to prepare (+/-)-5-hydroxy-3a-methyl-2,3,3a,8a-tetrahydro-furo[2,3-b]benzofuran, 10, and (+/-)-7-hydroxy-5-methyl-4,5-dihydro-2,5-methano-1,3-benzodioxepine, 14. Reduced reactivity relative to 5-hydroxy-3-methoxycarbonylmethylene-3-methyl-3H-benzofuran-2-one, 6, was preliminarily studied. Meanwhile, a plausible mechanism with regard to the formation of 10 and 14, which included cyclization, rearrangement, and ring expansion of hemiacetal, 15, is proposed. Specific carbamates of phenols, 10 and 14, have shown impressive inhibitory activities against human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) ex vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050674     DOI: 10.1021/jo0503052

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

Authors:  Weiming Luo; Qian-Sheng Yu; Santosh S Kulkarni; Damon A Parrish; Harold W Holloway; David Tweedie; Avigdor Shafferman; Debomoy K Lahiri; Arnold Brossi; Nigel H Greig
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

Review 2.  Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.

Authors:  Mohammad A Kamal; Shubha Priyamvada; Arivarasu N Anbazhagan; Nasimudeen R Jabir; Shams Tabrez; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

3.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

4.  Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.

Authors:  Mohammad A Kamal; Xianqin Qu; Qian-Sheng Yu; David Tweedie; Harold W Holloway; Yazhou Li; Yi Tan; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2008-01-31       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.